Inventory decreased 37.0%
Inventory changed -37.0% from the comparable as-filed period.
$1.2M→$728,0003 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →LVO financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Inventory / revenue moved 226 bp lower
Inventory / revenue changed -226 basis points from the comparable as-filed period.
6.02%→3.76%3 prior comparisons
Revenue increased 0.7%
Revenue changed +0.7% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
$19.2M→$19.4M3 prior comparisons
Capex / revenue moved 93 bp lower
Capex / revenue changed -93 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
5.31%→4.38%3 prior comparisons
Operating income increased 8.9%
Operating income changed +8.9% from the comparable as-filed period.
-$4.0M→-$3.7M3 prior comparisons
Working capital / assets moved 456 bp lower
Working capital / assets changed -456 basis points from the comparable as-filed period.
-22.50%→-27.05%3 prior comparisons
Capital expenditure decreased 16.9%
Capital expenditure changed -16.9% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
$1.0M→$848,0003 prior comparisons
Receivables / revenue moved 229 bp higher
Receivables / revenue changed +229 basis points from the comparable as-filed period.
43.35%→45.64%3 prior comparisons
Current liabilities increased 2.9%
Current liabilities changed +2.9% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
$34.0M→$35.0M3 prior comparisons
Cost of revenue decreased 8.4%
Cost of revenue changed -8.4% from the comparable as-filed period.
$16.8M→$15.4M3 prior comparisons
Research & development increased 4.3%
Research & development changed +4.3% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
$934,000→$974,0003 prior comparisons
R&D / revenue moved 17 bp higher
R&D / revenue changed +17 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
4.86%→5.03%3 prior comparisons
Current assets decreased 5.1%
Current assets changed -5.1% from the comparable as-filed period.
$22.9M→$21.8M3 prior comparisons
Trade receivables increased 6.1%
Trade receivables changed +6.1% from the comparable as-filed period.
$8.3M→$8.8M3 prior comparisons
Current ratio decreased 7.8%
Current ratio changed -7.8% from the comparable as-filed period.
0.68→0.623 prior comparisons
Total assets decreased 0.4%
Total assets changed -0.4% from the comparable as-filed period.
$48.9M→$48.7M3 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.